TrialHuman vaccines & immunotherapeutics2022

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial.

Wenjuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.